A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
- Conditions
- Interventions
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 178
- Registration Number
- NCT06321302
- Locations
- 🇺🇸
Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸American Institute of Research, Inc, Los Angeles, California, United States
🇺🇸NJRetina, Teaneck, New Jersey, United States
A Study in Healthy Japanese Men to Test How Well Different Doses of BI 3006337 Are Tolerated
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT06310005
- Locations
- 🇯🇵
Clinical Research Hospital Tokyo, Tokyo, Shinjuku-ku, Japan
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight
- Conditions
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 160
- Registration Number
- NCT06309992
- Locations
- 🇺🇸
Excel Medical Clinical Trials, Boca Raton, Florida, United States
🇺🇸Bruce A. Segal, MD, PA, Delray Beach, Florida, United States
🇺🇸Velocity Clinical Research-Gardena-69773, Gardena, California, United States
JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 299
- Registration Number
- NCT06287073
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷The Chatholic University of Korea, Eunpyeong St. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 204
- Registration Number
- NCT06280235
- Locations
- 🇺🇸
Southwest Biomedical Research, LLC, Tucson, Arizona, United States
🇺🇸Asclepes Research Centers-Panorama City-62905, Panorama City, California, United States
🇺🇸iResearch Atlanta, Decatur, Georgia, United States
A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver Problems
- First Posted Date
- 2024-02-22
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4
- Registration Number
- NCT06272058
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States
A Study in Healthy Men to Test How Different Doses of BI 3031185 Are Tolerated and How Food Influences the Amount of BI 3031185 in the Blood
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT06255340
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 39
- Registration Number
- NCT06241573
- Locations
- 🇦🇷
Hospital Alemán, Capital Federal, Argentina
🇧🇬Medical Center "Kordis", Pleven, Bulgaria
🇯🇵Tokyo Medical University Hospital, Tokyo, Shinjuku-ku, Japan
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
- Conditions
- Interventions
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT06241560
- Locations
- 🇬🇪
LTD The First Medical Center, Tbilisi, Georgia
🇬🇪LTD "Aversi clinic", Tbilisi, Georgia
A Follow-up Study to Test Long-term Treatment With BI 1015550 in People With Pulmonary Fibrosis Who Took Part in a Previous Study With BI 1015550
- Conditions
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1700
- Registration Number
- NCT06238622
- Locations
- 🇺🇸
Clinical Research Specialists LLC, Kissimmee, Florida, United States
🇺🇸Advanced Pulmonary Research Institute, Loxahatchee Groves, Florida, United States
🇦🇷Consultorios Médicos del Buen Ayre, Capital Federal, Argentina